3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
44
Lymphoma, Non-Hodgkin
12
Lymphoma, B-Cell
12
Lymphoma, Follicular
7
Lymphoma
7
Recurrence
5
Lymphoma, Mantle-Cell
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Lymphoma, B-Cell, Marginal Zone
3
Hodgkin Disease
2
Burkitt Lymphoma
2
Neoplasms
1
Leukemia, Hairy Cell
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
40
fludarabine
36
fludarabine phosphate
28
Tacrolimus
20
Whole-Body Irradiation
18
Mycophenolic Acid
18
Busulfan
18
Melphalan
16
thymoglobulin
14
Rituximab
13
Antilymphocyte Serum
12
venetoclax
11
Thiotepa
10
Nivolumab
9
Methotrexate
9
Granulocyte Colony-Stimulating Factor
9
Stem Cell Transplantation
8
Peripheral Blood Stem Cell Transplantation
8
Cyclosporine
8
trametinib
7
Sirolimus
7
Cytarabine
7
Azacitidine
7
AP 1903 reagent
7
Filgrastim
6
Dexamethasone
6
aldesleukin
5
Mesna
5
Ipilimumab
5
Interleukin-2
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
polatuzumab vedotin
×
Lymphoid
×
Clear all
NCT04844866
2026-04-29
DALY 2-EU
Miltenyi Biomedicine GmbH
Phase 2
Recruiting
213 enrolled